Catalog No.
KDB94404
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human TNFa has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Infliximab in the sample competitively binds to the pre-coated protein with biotin-labeled Infliximab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Infliximab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Infliximab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
93.75 - 3,000 ng/mL
Sensitivity
71.38 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
1618.8 |
386.8 |
130.5 |
1723.3 |
398.5 |
119.3 |
|
Standard deviation |
52.2 |
12.9 |
12.8 |
92.6 |
15.3 |
13.5 |
|
CV (%) |
3.2 |
3.3 |
9.8 |
5.4 |
3.8 |
11.4 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
TA-650, cA2, CAS: 170277-31-3
Background
Infliximab is a chimeric monoclonal antibody and used to treat auto- immune disorders. Infliximab reduces the amount of active human tumour necrosis factor alpha (hTNFa) in the body by binding to it and preventing it from signaling the receptors for TNFa on the surface of various cell types. TNFa is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis.
For research use only. Not for human or drug use.
